Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
March 11, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
February 22, 2021 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
February 19, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 05, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 13, 2020 08:05 ET
|
Vaccinex, Inc.
Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA®...
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
October 29, 2020 11:15 ET
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
October 29, 2020 07:55 ET
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
September 22, 2020 07:30 ET
|
Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
August 27, 2020 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 14, 2020 08:30 ET
|
Vaccinex, Inc.
On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised...